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It is unclear how loss-of-function germline mutations in the widely-expressed co-chaperone AIP, result in young-onset growth
hormone secreting pituitary tumours. The RET receptor, uniquely co-expressed in somatotrophs with PIT1, induces apoptosis when
unliganded, while RET supports cell survival when it is bound to its ligand. We demonstrate that at the plasma membrane, AIP is
required to form a complex with monomeric-intracellular-RET, caspase-3 and PKCδ resulting in PIT1/CDKN2A-ARF/p53-apoptosis
pathway activation. AIP-deficiency blocks RET/caspase-3/PKCδ activation preventing PIT1 accumulation and apoptosis. The
presence or lack of the inhibitory effect on RET-induced apoptosis separated pathogenic AIP variants from non-pathogenic ones.
We used virogenomics in neonatal rats to demonstrate the effect of mutant AIP protein on the RET apoptotic pathway in vivo. In
adult male rats altered AIP induces elevated IGF-1 and gigantism, with pituitary hyperplasia through blocking the RET-apoptotic
pathway. In females, pituitary hyperplasia is induced but IGF-1 rise and gigantism are blunted by puberty. Somatotroph adenomas
from pituitary-specific Aip-knockout mice overexpress the RET-ligand GDNF, therefore, upregulating the survival pathway.
Somatotroph adenomas from patients with or without AIP mutation abundantly express GDNF, but AIP-mutated tissues have less
CDKN2A-ARF expression. Our findings explain the tissue-specific mechanism of AIP-induced somatotrophinomas and provide a
previously unknown tumorigenic mechanism, opening treatment avenues for AIP-related tumours.
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INTRODUCTION
The pituitary gland contains five different endocrine cell types
with growth hormone (GH)-secreting cells, so-called somato-
trophs, contributing to ~50% of the gland. The transcription factor
PIT1 is required for the expression and secretion of GH. PIT1 is also
essential for somatotroph differentiation during embryonic devel-
opment and for proliferative and secretory response to the
hypothalamic factor GH-releasing hormone (GHRH) [1]. However,
when PIT1 is excessively accumulated in a somatotroph cell,
apoptosis is initiated resulting in the elimination of the cell [2, 3].
Somatotroph tumours secrete excess GH leading to acromegaly
or gigantism if started before epiphyseal closure and need to be
treated with surgery and pharmacological treatment [4–6]. Excess
GH and its target hormone IGF-1 causes enlarged organs, bone
and joint deformation, hypertension, diabetes and significantly
reduced life expectancy if left untreated [4, 5].
Germline mutations in the AIP gene is a known cause of familial
isolated pituitary adenoma (FIPA), mostly somatotrophinomas
[7–11]. Pituitary tumours associated with AIP mutations (AIP-FIPA)
are often invasive macroadenomas presenting in the second
decade. They are prone to pituitary apoplexy and respond poorly
to first-generation somatostatin analogue therapy. Genetic screen-
ing and clinical follow-up of carriers lead to earlier disease
detection and better outcomes [12].
AIP is a widely expressed co-chaperone and there is no clear
explanation why it predisposes to specifically pituitary somato-
troph or lactotroph tumorigenesis and no other tumours. It is
quite clear that the cAMP pathway is key in somatotroph
tumorigenesis and several lines of experimental results suggested
upregulated cAMP pathway, reduced Galphai-2 expression and
abnormal phosphodiesterase interactions, but none represent
pituitary-specific mechanisms [13–16]. Being a chaperone, not
surprisingly several novel interacting proteins have been
described for AIP [17] and miR34 has also emerged in two
independent studies as a related key microRNA [18, 19]. Knowl-
edge derived from cell-based experiments considers AIP as a
tumour suppressor in some cell types [7, 8, 15], but not all [20].
Global knockout in mice, Drosophila and C. elegans shows
embryonic lethality [21–23]. The global Aip heterozygous knock-
out mouse or conditional knockout restricted to Gh- (somato-
trophs) or Hex1-(pituitary) expressing cells present a phenotype
with pituitary tumours [24–27].
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The RET receptor is a tyrosine kinase with four ligands (GDNF,
NRTN, ARTM, PSPN) and four respective co-receptors (GFRα1-4).
RET is implicated in several diseases from neuroendocrine cancer,
such as medullary thyroid carcinomas and pheochromocytomas,
to developmental defects in parasympathetic neurons and the
urinary tract. Normal and tumorous somatotroph cells express RET,
GDNF and GFRα1 [28–30]. RET is active both in the absence and
presence of its ligands, therefore giving rise to two different
pathways. Both can be activated in somatotroph cells. In the
absence of the ligand GDNF, RET is intracellularly processed by
caspase-3 and induces the PIT1 promoter with massive PIT1
accumulation, resulting in the upregulation of the RET/PIT1/ARF/
p53-apoptotic pathway [2, 3, 30, 31]. At the PIT1 promoter,
activation is mediated by conserved CRE and c/EBP binding sites is
mediated by conserved CRE and c/EBP binding sites, following
activation of phospho-JNK [2]. Similarly, induction of the CDKN2A-
ARF promoter is mediated by a conserved PIT1 binding site [3]. On
the other hand, when RET is stimulated by its ligand GDNF, RET
dimerises and upregulates the GDNF/RET/AKT survival pathway
via its tyrosine-kinase activity, while maintaining PIT1 expression
at basal levels [2, 30, 31]. The two pathways are independent, as
kinase-dead RET point mutants in the presence of GDNF are
unable to activate the AKT pathway, but keep stimulating the
apoptotic pathway [2]. Thus, RET is a dependence receptor [32, 33]
for somatotroph cells, as they need the constant presence of
GDNF to survive. Both the RET-related survival (presence of RET
ligand) and apoptosis (lack of RET ligand) pathways are conserved
in sporadic somatotroph tumours [31] and recent results
demonstrated that i) overexpression of GDNF is a hallmark of
somatotroph tumours, and ii) lower level ARF expression is a
prognostic marker for resistance to therapy [30].
Although it was shown that RET can bind AIP in rat whole
pituitary extracts, molecular studies performed in HEK293 cells
with RET or AIP were unable to demonstrate any functionality of
this interaction, as it was not affected by any RET or AIP point
mutations [34]. Previously we had demonstrated that proliferative
responses to GHRH varied depending on the cell phenotype, and
this was specifically caused by differences in PIT1 expression [1].
We hypothesise that AIP has a role in RET-related survival and
apoptotic pathways specifically in somatotroph cells. In the current
study, we have explored the action of wild-type human AIP (wtAIP),
missense AIP variants identified in pituitary adenoma patients and
AIP repression (siRNA or knockout) on the RET/PIT1/ARF/p53-
apoptosis pathway, using well-characterized somatotroph cell lines,
primary pituitary cultures, a new rat model of gigantism/acromegaly
and a novel pituitary-specific Aip knockout mice.
RESULTS
Functional classification of AIP mutations into two groups:
protein present or absent
AIP is coded by a gene on 11q13 spanning six exons (Fig. 1A).
Various genetic alterations have been found in patients with
pituitary adenomas, such as whole gene or exon deletions,
promoter mutations, insertions/deletions, splicing mutations as
well as nonsense and missense mutations. While loss-of-function
truncating mutations are listed as pathogenic in databases, many
missense variants are listed as Variants of Uncertain Significance
due to lack of convincing clinical data and shortage of functional
data (Fig. 1B). We have selected nine AIP variants identified in
patients (Supplementary Table 1), some with previous attempts at
functional characterization [8, 9, 14, 22, 35]. In silico analysis with
17 available algorithms showed lack of consensus regarding the
pathogenicity of these variants (Supplementary Table 2).
The selected human AIP variants, as well as wtAIP, were cloned
in a vector including an N-terminal MYC-tag. Variants were
transfected into rat GH4C1 somatotroph cells, which endogen-
ously express PIT1, GH and RET pathway members GDNF and
GFRα1 at similar levels to normal rat pituitary tissue (Supplemen-
tary Figure 1B–D). However, GH4C1 cells poorly express RET
receptor at both mRNA and protein levels (Supplementary Figure
1B, C). These data are in keeping with our previous studies using
Northern blots, and our previous repeatedly failed attempts to
stably express RET in GH4C1, leading to the discovery of the RET-
apoptotic pathway in somatotroph cells [2]. When cells were
deprived of serum (0.1% FBS), intracellular sorting of GDNF and
GFRα1 proteins was arrested, and GH expression was down-
regulated (Supplementary Figure 1C, D).
Anti-AIP antibody detected both endogenous rat and exogen-
ous human AIP protein, while transfected AIP protein could be
detected through the MYC-tag antibody as well. Half-life of the
nine selected AIP variants in pituitary cells did not change in
presence of human RET (Fig. 1B, C), similarly to data previously
studied in HEK293 cells for some of the variants [17, 36]. Rat Aip
siRNA silencing was chosen as a strategy to explore the activity of
those unstable AIP variants (Fig. 1D).
Pathogenic AIP variants or Aip repression block the RET/PIT1/
CDKN2A-ARF/p53 apoptotic pathway specifically in pituitary
somatotrophs
Our previous results have characterized precisely that GH4C1 cells
transfected with RET, either the short (RETS, 1072 amino acids) or
the long (RETL, 1116 amino acids) isoforms, start to die 48 h after
deprivation of RET ligand GDNF, and this was prevented by
addition of exogenous recombinant GDNF.
We transfected wt or variant AIP plasmids into GH4C1 cells in the
absence or presence of RETS and evaluated apoptosis by Hoechst
33258 staining, a system model in which we had extensive previous
experience as an indicator of the activity of the RET-associated
apoptotic pathway [2, 3] (Fig. 2A, B and Supplementary Figure 2A).
Apoptosis was confirmed by a caspase-based fluorescent cellular
assay and cell numbers (Supplementary Figure 2A–E).
The basal apoptosis rate in the absence of RET was not affected
by any of the AIP variants, except the V49M variant that doubled
the basal apoptosis rate (Fig. 2A). This germline variant was
identified in a patient with gigantism but no loss-of-
heterozygosity was detected in the somatotrophinoma tissue [37].
RETS transfection enhanced more than four times the rate of
apoptosis in GH4C1 cells with or without wtAIP co-transfection
(Fig. 2B). Apoptosis was prevented by GDNF, indicating that
expression of wtAIP did not alter GDNF-induced RET activation
and survival.
However, when some of the variant AIP plasmids were co-
transfected with RETS, apoptosis was strongly and significantly
reduced in the absence of GDNF (Fig. 2B). Similar results were
obtained for RETL (Fig. 2B).
AIP variants R16H, V49M, C238Y, I257V, R271W, R304Q, R325Q
prevented RET-dependent apoptosis, while R188Q and E245K did
not alter RET-induced apoptosis (Fig. 2B). These two variants were
actually found in patients with sporadic microprolactinoma and
sporadic macroprolactinoma, therefore not the most typical
characteristics associated with AIP mutations (Supplementary
Table 1), had normal half-life and were considered non-
pathogenic in the majority of algorithms in our in silico assessment
(Supplementary Table 2). Of all the in silico algorithms, the most
recent CADD 1.6 classification of the AIP variants coincided with
the results from the apoptosis assay in pituitary cells (Fig. 2B and
Supplementary Table 2). Based on these data, we divided the
variants we tested into ‘our pathogenic’ (R16H, V49M, C238Y,
I257V, R271W, R304Q, R325Q) and ‘our benign’ variants (R188Q
and E245K) for further experiments.
Our results in somatotrophs show inhibition of RET-induced
apoptosis by mutated AIP, while a previous study in HEK293 found
no effect [34]. Therefore, we repeated our experiments in HEK293
and found no inhibition on RET-induced apoptosis in our
pathogenic variants (Fig. 2C), confirming the previous data. These















results indicate that the effect of variant AIP was specific for
pituitary cells expressing Pit1. While PIT1 plays a key role in the
RET-related apoptotic pathway (Fig. 2D) [2, 3, 30], we considered
that in somatotroph cells, wtAIP could be either implicated in
promoting the RET-apoptotic pathway or in blocking the RET-
survival pathway. Pathogenic AIP variants could either lack
apoptosis-supporting activity of wtAIP or promote the RET-
survival pathway even in the absence of GDNF.
To explore these questions, we studied PIT1/ARF/p53 expres-
sion (Fig. 2E). Cells co-transfected with RET and wtAIP increased
PIT1, ARF and p53 expression. RET co-transfected with any AIP
variant that blocked apoptosis (R16H, V49M, C238Y, I257V, R271W,
R304Q, R325Q) did not present stimulated PIT1 expression and
consequently had no ARF or p53 increase. AIP variants that did not
block RET-induced apoptosis (R188Q, E245K) showed increased
PIT1, ARF and p53 expression, similar to wtAIP (Fig. 2E). To confirm
again the importance of the cell type, we repeated these
experiments in HEK293 cells: here RET expression induces ARF
and p53 expression and the presence of wtAIP or variant AIP does
not change this induction (Fig. 2F).
Next we studied the functional effect of endogenous Aip
downregulation in GH4C1 cells. After GDNF deprivation, RETS
induced apoptosis in the presence of scrambled (Sc) siRNA
corresponding to increase in the expression of PIT1, ARF and p53
(Fig. 2G). Aip siRNA blocked RET-induced apoptosis in correlation
with repressed PIT1, ARF and p53 levels.
A more physiological model was tested for the pituitary-specific
effect of AIP. Primary pituitary cultures are a mix of cells with
around 50% somatotroph cells. We transfected empty vector,
wtAIP or three AIP variants (V49M, R304Q, R325Q) and tested the
endogenous RET-apoptotic pathway (Fig. 2H). After GDNF depriva-
tion, 50% of the cells had died and this was not altered by
exogenous human wtAIP since PIT1, ARF and p53 were induced.
AIP variants blocked apoptosis as efficiently as exogenous GDNF,
Fig. 1 Strategy to study the two groups of AIP variants: shorter and normal half-life. A Left: Cartoon showing the human AIP gene, mRNA
and protein. The studied variants are indicated. Right: AIP gene variants described in Ensembl (data retrieved at 06/20/2020), indicating how
many of each type of variants is considered as pathogenic, likely pathogenic (Likely p.) as opposed to Variants of Uncertain Significance, likely
non-benign or benign. Variants could be grouped based on their protein half-life. B Wild-type human AIP (wtAIP) or variant AIP were
expressed in the pituitary somatotroph rat cell line GH4C1 with an N-terminal MYC-tag. Western blot against AIP detected endogenous rat AIP
together with exogenous human AIP. MYC western blot exclusively detected transfected human AIP. R304* AIP is undetectable under our
experimental conditions presenting a very-short half-life, R271W and C238Y present short half-life in comparison to wtAIP, while R16H, V49M,
R188Q, E245K, I257V, R304Q and R325Q AIP variants present normal half-life compared to wtAIP. C Co-transfection of RET receptor does not
alter the half-life distribution of wtAIP or AIP variants. D Aip siRNA is able to downregulate endogenous rat AIP protein expression as a model
for AIP deficiency in GH4C1 cells.
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since they blocked PIT1 induction and consequently, ARF and p53
protein levels were low (Fig. 2H). In primary pituitary cultures,
repression of endogenous Aip with siRNA blocked the endogenous
RET-apoptotic pathway similar to GDNF, with reduced expression
of PIT1, ARF and p53 levels (Fig. 2I).
Finally, to test which stage of the RET pathway is influenced by
AIP, we transfected GH4C1 with intracellular (IC)-RET instead of
full-length RETS together with wtAIP, variant AIP (V49M, R304Q) or
Aip siRNA (Fig. 2J). In the presence of the 707-1017 intracellular
portion of monomeric RET (IC-RET), AIP variants or Aip siRNA did
not present any anti-apoptotic effect and PIT1/ARF/p53 were fully
induced as in wtAIP. This suggests that AIP could be involved in
the generation of the intracellular RET fragment. The RET-induced
mRNA expression of the two key regulated genes Pit1 and Arf is
stimulated by wtAIP and inhibited by AIP variants or Aip siRNA
(Supplementary Figure 3A–G). This indicated that AIP acts on the
RET-apoptotic pathway through a mechanism upstream of Pit1
induction. We investigated the first step in the pathway. In cells
transfected with RETS+wtAIP, 1 hour after GDNF deprivation RET
could be detected as a full-length double band of 170 kDa plus a
strong band of around 42 kDa corresponding to one C-terminal
tail cut by caspase-3 at position 707 (707-1072) and a smaller and
weaker band ≤40 kDa corresponding to IC-RET, cut twice by
caspase-3 (positions 707-1017) (Supplementary Figure 3H). These
data identified a novel mechanism and provide an explanation for
the observed reduced apoptosis: AIP variants prevented RET
processing and IC-RET generation (Supplementary Figure 3H). On
the other hand, AIP variants did not activate the survival pathway
since no differences were found in AKT phosphorylation
(Supplementary Figure 3H).
AIP is essential for the initiation of the RET-apoptotic
pathway: effect on caspase-3 and PKCδ
To investigate the role of AIP in the early initiation of the RET-
apoptotic pathway, we standardized subcellular extracts charac-
terized in Supplementary Figure 4.
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We selected fraction 1, enriched in plasma membrane proteins,
for further experiments comparing all AIP variants (Fig. 3). Cleaved
caspase-3 was undetectable in the presence of RETS with any
variant in comparison to RETS with wtAIP (Fig. 3A). Similar results
were obtained for IC-RET or p-PKCδ, detected only in RETs with
wtAIP (Fig. 3A). Total PKCδ presented two bands since it is also a
substrate of caspase-3. The lower band (processed PKCδ) was high
in RETS with wtAIP and reduced with all AIP (pathogenic) variants.
p-JNK or p-CREB did not present a consistent pattern at this time,
but they are late proteins in the pathway and needed a longer
time course. Cells transfected with RETS and Aip siRNA presented
no evidence of cleaved caspase-3, IC-RET, p-PKCδ, p-JNK or p-CREB
compared to RETS with control Sc siRNA (Fig. 3B).
Measuring caspase-3 activity at 1 hour showed that variant AIP
or Aip siRNA blocked RET-induced caspase-3 activity corroborating
the consequent effects on apoptosis (Fig. 3C).
To demonstrate that PKCδ activation was essential in the
pathway, we transfected a PKCδ kinase-dead point mutant, K376R
(Fig. 3D). This mutant was able to block PIT1/ARF increase and
apoptosis in cells transfected with RETS and wtAIP. One hour after
deprivation, PKCδ-K736R did not present RET-induced PKCδ
phosphorylation, but did not affect IC-RET processing (Fig. 3D).
Interactions between RET, caspase-3, PKCδ and AIP: effects of
AIP variants
RET (and IC-RET), caspase-3 and PKCδ form a complex [2]. AIP has
been demonstrated to bind to RET in HEK293 cells and in whole
pituitary extracts [34]. To determine if AIP was able to bind all the
proteins in this complex in somatotrophs, we transfected cells
with the MYC-tagged wtAIP and RET and immunoprecipitated AIP
with anti-MYC tag antibody (Fig. 4A left). Full-length caspase-3,
both bands of PKCδ, and RET were easily detected in these
pulldowns. For RET, the major band was IC-RET, although full-
length RET could be also detected. When anti-PKCδ was used for
immunoprecipitation, AIP (both with anti-MYC and anti-AIP),
caspase-3 and RET were also detected (Fig. 4A right).
To dissect the molecular interactions between the four proteins
through the AIP variants, we cloned all MYC-tagged AIPs in the
MIGR1 vector containing the IRES motive followed by EGFP
(Fig. 4B). In this way, for each AIP protein molecule translated,
there will be approximately one molecule of EGFP. We used this
system to equalize for protein expression of each variant in
transfected cells. Following this, we performed a Proximity
Ligation Assay (PLA) to explore direct interaction (<40 nm) of
AIP with these three proteins [38, 39]. Using anti-MYC antibody
(mouse origin) and anti-RET, anti-caspase-3 or anti-PKCδ anti-
bodies (rabbit origin) we quantified the spots after normalization
by EGFP expression. The RET-AIP PLA assay determined that
R325Q AIP variant abolished, and I257V reduced, the interaction
while R16H and R304Q enhanced the interaction (Fig. 4C). The
caspase-3-AIP PLA assay determined that V49M, I257V and R325Q
AIP variants abolished interaction (Fig. 4D). The PKCδ-AIP PLA
assay determined that R16H and R304Q variants abolished the
interaction while V49M and R325Q enhanced the interaction (Fig.
4E). The GFP-AIP PLA assay as well as the absence of primary
antibody did not show any interaction (Fig. 4F).
A 3D model [40, 41] based on a monomer [42, 43] explained our
PLA assay results (Extended text and Supplementary Figure 5).
Based on these data, lack of AIP or presence of our pathogenic AIP
variants may disrupt the RET/caspase-3/PKCδ/AIP complex result-
ing in reduced JNK activation and reduced apoptosis.
AIP variants expressed in the pituitary affects postnatal
growth in vivo
We wanted to test AIP point mutations individually in relation to
the RET pathway in a high-throughput way without having to
generate a new genetically modified mouse for each mutation. In
the first week of life, rodent pituitary undergoes somatotroph cell
expansion with active cell proliferation of the stem population and
quick differentiation into somatotroph cells [44, 45]. Retroviruses
specifically infect actively proliferating cells [46]. We incorporated
into the viral injection the two key neuroendocrine hormones
driving somatotroph proliferation, GHRH and ghrelin, to reinforce
somatotroph-specific infection (Supplementary Methods). Follow-
ing optimalisation, we developed a new model to inject the
pituitary through the ear canal immediately after birth, allowing
early testing of gene variants.
We prepared MIGR1 retrovirus bearing vector alone, wtAIP, all of
our four stable (R16H, V49M, R304Q and R325Q) and one of our
unstable (C238Y) pathogenic AIP variants, and validated them in vitro
(Supplementary Figure 6A–C). The possibility that an unstable AIP
variant had a functional effect had mixed odds. On the one hand, the
used MIGR retroviral vector has a strong promoter. On the other
hand, the rat pituitary cells conserved their own two endogenous
normal Aip alleles. Based on CADD v1.6 scores (C238Y 26.9, R271W
24.7 (see Supplementary Table 2)) and our previous functional data
[8, 14, 17], we selected this variant for in vivo study. Retroviruses were
injected into male Sprague-Dawley rats at P1 (Fig. 5A). EGFP
fluorescence was detected in the three pituitary lobes using 3D
light-sheet microscopy one week after injection of wtAIP retrovirus
Fig. 2 Variant AIP or Aip downregulation blocks the physiological RET/PIT1/CDKN2A-ARF/p53 apoptosis pathway. A Expression of wt or
variant AIP does not affect basal rate of apoptosis when GH4C1 cells are deprived of GDNF (0.5% FBS). V49M is the only variant causing some
apoptosis. B When RETS is transfected in GH4C1, serum deprivation induces the RET-apoptotic pathway (black bar) that is blocked by the RET
ligand GDNF (black hatched). Expression of human wtAIP together with RET maintain the apoptotic pathway which is also blocked by GDNF
(grey colour, black hatched). Expression of variant AIP (R16H, V49M, R271W, C238Y, I257V, R325Q, coded coloured bars) blocks RET-induced
apoptosis in the absence of GDNF. RETL expression follows the same pattern with strong apoptosis in the presence of wtAIP (grey bar) blocked
by variant AIP in the absence of GDNF. Expression of R188Q or E245K (coded coloured bars), does not block RET-induced apoptosis. C A similar
experiment in the embryonic kidney cell line HEK293T cells have different results. RET induces apoptosis in the presence of wtAIP but also in
the presence of any AIP variant. D Cartoon showing the known RET pathways in pituitary somatotroph cells: left, RET/PIT1/CDKN2A-ARF/p53
apoptosis pathway; right, RET/GDNF-AKT survival pathway. AIP alteration could affect any step in the apoptotic pathway or directly induce the
survival pathway. E AIP variants that block apoptosis also prevent RET-induced Pit1 overexpression, p19Arf increase and p53 accumulation.
The two AIP variants that did not block apoptosis did not alter RET-induced Pit1 overexpression, p19Arf increase and p53 accumulation.
F HEK293T does not express PIT1 and express large T-antigen. However, RET expression induces ARF and p53 accumulation in the presence of
WT or variant AIP. G In GH4C1 repression of endogenous Aip blocks RET-induced apoptosis in parallel to PIT1, ARF and p53 repression.
H, I Similar results were obtained in rat male primary pituitary culture with 45%-50% somatotroph cells expressing endogenous rat RET
receptor. HWhen cultures are serum-deprived (no GDNF) apoptosis is induced, and this is prevented by the addition of rGDNF. Transfection of
wtAIP does not alter apoptosis, nor the apoptotic pathway through PIT1/ARF/p53 accumulation. Transfection of variant AIP blocks PIT1/ARF/
P53 increase and apoptosis. I Repressing Aip with siRNA blocks PIT1/ARF/p53 increase and apoptosis as well as GDNF addition. J In GH4C1,
direct transfection of the short caspase-processed intracellular RET fragment, IC-RET, induces the RET/PIT1/CDKN2A-ARF/p53 apoptosis
pathway that cannot be blocked by AIP mutants or rAip siRNA. (One-way ANOVA with Tukey’s multiple comparison test correction A, J left;
Two-ways ANOVA with Sidak’s multiple comparison test correction B-C-G-H-I-J right. **, p < 0.01; ***, p < 0.001; ns non-significant).
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(Fig. 5B). Somatotroph specificity of the infection was tested in
through immunofluorescence colocalization with PIT1 and GH. Four
weeks after injection of wtAIP retrovirus, triple immunofluorescence
demonstrated massive co-localization of GH and EGFP (cytoplasmic)
together with PIT1 (nuclear) (Fig. 5C).
The litter number was adjusted for each mother. Two weeks
after injection, animals were weaned, identified, weighted, and
randomized. Animals were weighed weekly and at week 16,
animals were anesthetized, measured, and serum and tissue
samples were taken (Fig. 5A). Measures have been previously
A.R. Garcia-Rendueles et al.
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demonstrated as bona fide markers of rodent growth and GH
action [47–50]. At 16 weeks male animals injected with AIP
variants showed significantly higher IGF-1 serum levels compared
to wtAIP or MIGR1 vector alone injected animals (Fig. 5D). Variant
AIP-injected male rats were longer in total length, tail length and
body length (Fig. 5E and Supplementary Figure 6D), and showed
significantly longer back paws, front paws, ears, head and incisors
(Fig. 5F and Supplementary Figure 6D).
Excess GH results in cardiac hypertrophy in humans. Variant AIP-
injected male rats presented significantly larger hearts (Fig. 5G).
Pituitary weights had a tendency to be larger in variant AIP
pituitaries reaching significance in two groups (Supplementary
Figure 6D). Other organs, like the liver, did not show significant size
change as expected (Supplementary Figure 6D). Patients with
acromegaly show increased weight and lean body mass. Variant AIP-
injected male rats presented significantly higher weights (Fig. 5H).
When body composition was assessed using MRI, a significant
increase in lean mass was observed in the male rats injected with
AIP variants in comparison with wtAIP or MIGR1 vector (Fig. 5H).
It is known that each endocrine cell-type in the pituitary have a
particular geographical distribution. Somatotrophs are concen-
trated in the lateral parts of the gland [51, 52]. In pituitaries of
adult rats injected at birth, GFP cells were concentrated at the
periphery of the pituitary lobes where somatotroph cells reside
and co-expressed PIT1 (Supplementary Figure 6E). Next, we
studied the pituitaries to determine if the phenotype induced
by the variant AIP could be related in vivo to the RET-apoptotic
pathway.
Male rats injected with variant AIP had a significantly lower
percentage of cells positive for cleaved caspase-3, IC-RET and p-
PKCδ (Fig. 6A) compared to wtAIP, while there was no difference in
the percentage of GFP cells (EGFP expression) between the groups.
The adenohypophysis area in the sections of the variant AIP injected
male pituitaries was significantly larger than wtAIP (see below).
Haematoxylin-eosin staining did not detect any adenomas, but
reticulin staining was disrupted in AIP variant-injected pituitaries that
showed pituitary hyperplasia with larger acini (Fig. 6B).
We prepared protein extracts from frozen pituitaries and run 20
parallel samples, four-five per condition (Supplementary Figure
6F). Global levels of p-PKCδ and relative p-PKCδ/total PKCδ were
significantly reduced in variant AIP-injected animals in comparison
with wtAIP or MIGR1 vector (Fig. 6C). p-JNK levels were also
significantly reduced although some variant AIP groups did not
reach significance (Fig. 6C). IC-RET levels were found to be
significantly reduced in some variants although not in all (Fig. 6C).
Cleaved PARP, a marker of active apoptosis in pituitary tissue [2]
was significantly reduced in several groups of variant AIP-injected
animals although not in all (Fig. 6C). PIT1 is a transcription factor
common to somatotroph, lactotroph and thyrotroph cells.
Although PIT1 protein detection by western blot was not specific
for the somatotroph fraction, PIT1 protein levels were significantly
reduced in two variants (R16H and R325Q) and reached p= 0.2 in
the other three (V49M, R304Q and C238Y) (Data not shown). AIP
protein expression had a tendency to be higher in pituitaries
expressing human exogenous AIP (including wtAIP), but only
reached significance in the V49M group. MYC expression, on the
other hand, was only present in the rats infected with (MYC-)AIP-
expressing virus at around 35 kDa (Data not shown). This MYC
band was abundant in variant AIP pituitaries compared to wtAIP.
No significant differences were found for full-length RET or GFP.
The results gathered with our in vivo model in male rats confirm
the data found in vitro in GH4C1 cells and in primary pituitary
cultures, demonstrating the role of AIP in the RET-apoptotic
pathway. Moreover, the data in vivo confirmed the role of AIP
variants implicated in AIP-FIPA blocking this pathway.
Results in female rats showed an attenuated phenotype
(Extended text and Supplementary Fig. 7), although significant
hyperplasia was present in both sexes in variant AIP pituitaries
(Supplementary Figure 7H).
Recently, we have shown that human somatotroph sporadic
adenomas without germline AIP mutation have an activated RET-
GDNF survival pathway, with high GDNF levels [30]. We studied a
second in vivo model, a pituitary-specific homozygous Aip
knockout and explored the RET pathways in the pituitary tissues.
15 months old AipFlox/Flox;Hesx1Cre/+ animals have a homozygous
Aip deletion in the pituitary-derived epithelium and develop GH-
secreting pituitary tumours [27]. Protein extracts from male Aip-
knockout pituitaries compared to AipFlox/Flox;Hesx1+/+ show a
significant increase in GDNF and phospho-AKT/total AKT and
phospho-mTOR/total mTOR ratios and reduced phospho-p53
expression (Fig. 7A, B). Total AIP protein levels were reduced but
not totally absent, since only the endocrine epithelium expressing
Hesx1 is affected (Fig. 7A (right)-B) [53, 54]. These results indicate
that Aip-knockout pituitary adenomas in mice have an upregu-
lated RET-GDNF/survival pathway, similar to human sporadic
somatotroph adenomas, and also decreased apoptosis.
To explore if human AIP-FIPA somatotroph adenomas also
conserved the RET-GDNF pathway, we performed studies in two
directions. Results based on Affymetrix probes from GSE63357 [55]
did not found differences in RET, GDNF, GFRA1, PIT1 or TP53 RNA
expression between sporadic and AIP-FIPA pituitary adenomas
(Extended text and Supplementary Fig. 8A–D and E). The CDKN2A
gene (coding for p19ARF and for p16) was represented by three
probes. We found reduction of expression in AIP-FIPA tumours
compared to sporadic adenomas for probe 209644_x_at directed
to the Exon 1 of the p19ARF isoform (Fig. 7C and Supplementary
Fig. 8F, G), while no difference was found for probe 211156_at
directed to the Exon 1 of the p16 isoform or for probe 207039_at
directed to the common Exon 3 for both isoforms. Furthermore,
recently we have generated novel unpublished data using RT-
qPCR with TaqMan probes where ARF expression is low in AIP+
human tumour vs controls (Alvarez and co-workers, unpublished).
Our previous data showed that high ARF mRNA level (relative
expression >0.1) in the tumour corresponds to a good response to
somatostatin analogues, while low ARF expression (<0.1) indicated
resistance to somatostatin analogues [30]. The AIP+ tumour
present ARF levels around 0.01 compared to 44 sporadic
somatotrophinomas responsive to somatostatin analogues, group-
ing with 13 unresponsive sporadic somatotrophinomas (Alvarez
and co-workers, unpublished). At the protein level, no suitable
Fig. 3 AIP variant or Aip repression alter the RET-apoptotic pathway at an early step: inhibition of caspase-3 and PKCδ activation.
A Plasma membrane fractioning extracts 30min after low serum conditions show that variant AIP block early caspase-3 cleavage and
activation. At 1 h, intracellular IC-RET processing is downregulated in the presence of variant AIP. p-PKCδ is concordantly downregulated.
p-JNK is also blocked. This time is too early to see any consistent change in p-CREB, previously described after 24 hours of GDNF deprivation. B
rAip siRNA blocks caspase-3 cleavage and activation together with p-PKCδ induction. In this case, p-JNK and p-CREB increases are also blocked
by rAip siRNA, indicating different time-course than with variant AIP transfection. Caspase-3 processed IC-RET bands are downregulated in the
presence of rAip siRNA. C Quantification of caspase activity shows that caspase-3 activation is an early event after GDNF deprivation that can
be blocked by the caspase-3 peptide inhibitor DEV-CHO or variant AIP or rAip siRNA in a similar fashion. This corresponds well with the later
detected apoptosis. D Apoptosis is absolutely dependent on PKCδ activity since the kinase-dead mutant K376R PKCδ blocks RET with wtAIP
dependent apoptosis. Kinase-dead PKCδ does not alter IC-RET processing by caspase-3. (Two-ways ANOVA with Sidak’s multiple comparison
test correction C-D. ***, p < 0.01).
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antibody for immunohistochemistry specific for ARF is available.
We performed immunohistochemistry for RET (total RET,
HPA008356), GDNF and GFRα1 comparing five sporadic (Sp GH)
and five AIP+ somatotroph adenomas (Fig. 7D, E). No difference
was seen between sporadic and AIP+ samples for RET, GFRα1 and
GDNF regarding intensity of the staining. However, comparing
corresponding areas on consecutive sections stained for GH
and for GDNF, we found more heterogeneous staining of GDNF in
AIP+ tumours with negative populations interspersed with the
stained cells in some samples (Fig. 7D, F). The relatively lower
GDNF would argue that a less stimulatory pathway is needed in
these samples to compensate for the already downregulated
apoptotic pathway, and GDNF would be useful exclusively to
promote growth. This could be explored in future studies.
DISCUSSION
We identified that AIP is needed for the normal functioning of the
RET/Pit1/ARF/p53-apoptosis pathway (Graphical Abstract, Supple-
mentary Fig. 9). This is disrupted by Aip knockdown, or with
overexpression of deleterious AIP variants. While the pathogenic role
of truncating AIP variants is established, there are controversies with
some missense variants, similar to all other fields of clinical genetics.
The data from our in silico assessment of AIP variants using CADD
v1.6 corresponded to the blocking effect on the RET-apoptotic
pathway (R16H, V49M, C238Y, I257V, R271W, R304Q and R325Q). Two
other missense AIP variants, R188Q and E245K (considered as benign
in CADD v1.6) do not affect the RET-apoptotic pathway, suggesting
that these are non-pathogenic variants [56, 57]. We note that three
from the variants showing disruption of the RET apoptosis pathway
in our studies here (R16H, R304Q and R325Q) have been suggested
in other studies (for example, [58], and including our own), to be
Variants of Uncertain Significance or possibly likely benign variants,
while data here suggest some functional shortcomings. Many other
studies suggest a clinical effect (revised in Supplementary Table 1 for
each variant). This is a controversy occurring increasingly in clinical
and experimental genetic studies probably due to differing
experimental models and genetic background of patients. Further
clinical and experimental experience may help to resolve these issues
in the future. In our in vitro and in vivo models, deleterious AIP
variants behave as dominant-positive, contravening the RET pathway
despite the two normal endogenous rAip alleles. We might speculate
that AIP-FIPA could be along the spectrum of gene–dosage
mechanism of tumour suppressors, as has been suggested for other
Fig. 4 Molecular interactions between AIP, RET, PKCδ and caspase-3 are altered by either N-term or C-term AIP point mutations. A wtAIP
(MYC-tagged) binds with RET, PKCδ and caspase-3 at the cytoplasm as shown by anti-MYC immunoprecipitation of plasma membrane/
cytoplasm extracts (1) and nuclear extracts (3), obtained 1 hour after serum deprivation. As control, a blank (B) immunoprecipitation with
antibody and beads without cell extracts. Left: RET, IC-RET, caspase-3, PKCδ and AIP are co-immunoprecipitated with anti-MYC-tag antibody.
Right: RET, caspase-3, AIP and PKCδ are co-immunoprecipitated with PKCδ antibody. In both types of immunoprecipitations, a very slight band
of PKCδ or MYC-Aip can be detected in the nuclear fraction. B Cartoon showing the constructs designed for the quantitative study of the
interaction of wtAIP or each AIP variant with RET, caspase-3 and PKCδ through PLA assay. Each construct expressed similar amounts of AIP and
EGFP, detected with GFP antibody and used as reference value in each cell. C-F PLA assays 1 hour after deprivation. C PLA assay between RET
and AIP (MYC-AIP). I257V and C-terminal R325Q variant significantly reduces the interaction: representative confocal microphotographs and
quantification (n= 6 per AIP variant). D PLA assay between caspase-3 and AIP. Both N-terminal V49M and C-terminal R325Q variants, together
with I257V, significantly reduce the interaction. E PLA assay between PKCδ and AIP. Both N-term R16H and R304A variants significantly reduce
the interaction, while V49M and R325Q enhanced the interaction, these are the residues that interact with caspase-3. I257V does not alter the
interaction. (One-way ANOVA with Holm-Sidak’s multiple comparison test correction C; Kruskal-Wallis with Holm–Sidak’s D, Dunn’s multiple
comparison test correction (E, F). **, p < 0.01; ***, p < 0.001; ns non-significant).
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tumour suppressors [59]. In carrier subjects, mechanisms of
regulation of the expression of the deleterious inherited variant
(methylation, lncRNA, microRNA or other) dependent on each
individual could modulate the penetrance of the disease, i.e. the
appearance of the pituitary tumour.
RET had initially been proposed as a ‘dependence receptor’ in
peripheral autonomic neurons as a mechanism explaining
Hirschprung’s disease [32]. Apoptotic pathways associated with
dependence receptors are often tissue-specific and frequently
implicate enzymatic intracellular cleavage of the monomeric
A.R. Garcia-Rendueles et al.
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receptor by caspases or other enzymes, with different down-
stream apoptotic pathways [33]. Why do tissues need a
dependence pathway? Dependence receptors have been referred
to as “guardians of tissue homeostasis and cancer prevention”
[33], since their pro-death activity observed upon ligand limitation
is implicated during embryonic development. Abnormal inhibition
of the pro-death activity of these receptors is associated with
tumour progression.
The discovery of the postnatal pituitary stem cell niche
expressing RET and GFRα co-receptors [44] led to the knowledge
that new progenitors are constantly being recruited and
differentiated into secretory endocrine cells in the pituitary
[60, 61]. The mechanism of postnatal differentiation of somato-
troph cells is not fully understood yet [62]. There is a slow cell
turnover from a PIT-negative progenitor to a PIT1 positive
somatotroph. Both too much PIT1 or too little would lead to
abnormalities. The Ret-knockout mouse presents a larger pituitary
gland with enhanced number of PIT1+ and GH+ cells [2]. This
mouse model dies postnatally due to the absence of parasympa-
thetic innervation in the bowels [63], so the postnatal endocrine
phenotype cannot be elucidated.
While the RET-related pituitary studies were concentrating on
somatotrophs [2, 3], RET expression has been demonstrated in rat
lactotroph cells in lactating dams, when weaning is finished and
there is a need for reduction of the lactotroph population through
apoptosis [64]. Moreover, an in vivo model of lactotroph hyperplasia
expressing RET showed a similar dependence-receptor pathway as
in the somatotrophs [2]. This suggests that, although somatotrophs
are the main population related to RET functionality, lactotrophs also
rely on this pathway for apoptosis, therefore disruption may lead to
lactotroph tumours; indeed, the first pure prolactinoma AIP-FIPA
family has been recently described [65].
From the molecular point of view, AIP´s role is at the initiation of
the RET-apoptotic pathway. AIP is directly associated with the
quadrimeric complex formed by the intracellular portion of
monomeric RET, caspase-3 and PKCδ, as shown by our PLA data.
Functional PLA assays also helped us to assess the effect of missense
AIP variants in the formation of this complex. The I257V and R325Q
variant impinged on RET binding, three variants blocked caspase-3
binding (V49M, I257V, R325Q) and two impinged on PKCδ binding
(R16H, R304Q). Variants that alter caspase-3 binding increased
association to PKCδ (V49M, I257V, R325Q); variants that alter PKCδ
binding increased association to RET (R16H, R304Q). In the absence
of AIP, the complex could not be formed at all. The exploratory in
silico molecular model suggests AIP acting as a monomer, as have
been previously suggested [43]. This three-dimensional model fits
with the functional data and the PLA assay. Our data also suggest
that caspase-3 activation and IC-RET processing is preceding PKCδ
activation, since a kinase-dead PKCδ also blocks the pathway but
does not prevent IC-RET processing. These positions AIP at the
cytoplasmic aspect of the plasma membrane, representing a link
between RET and the caspase-3-PKCδ complex, as the key link
between these enzymes and RET. PKCδ is an enzyme strongly
implicated in differentiation/apoptosis in various human cell types
[66, 67]. PKCδ is first phosphorylated followed by proteolytic
cleavage by caspases to obtain the pro-apoptotic catalytic fragment
[66]. The main caspase implicated in this action is caspase-3 [66].
Two models are proposed for apoptotic caspase-3 activity
initiation, either an auto-regulatory cis/trans activation induced by
aggregation / co-localization of protomers; or that once aggregation
/ co-localization of protomers is initiated the already present low
amount of non-apoptotic active caspase-3 present in the cell is
enough to initiate the cascade of auto-activation [68]. For caspase-3
activation in pituitary somatotrophs two conditions are required:
presence of RET and absence of GDNF (i.e. low serum). RET
transfection or empty vector transfection per se do not activate
caspase-3 activity in somatotrophs in either of the two models we
used ((i) GH4C1 cell line with exogenous RET transfection or (ii)
somatotroph primary cultures having endogenous RET expression)
(Fig. 2B, G, H, I). Our previous work has demonstrated that the RET
point-mutant at D707N binds to caspase-3 but is unable to induce
caspase-3 activity after deprivation of GDNF; correspondingly,
caspase-3 is unable to process RET D707N [2]. Moreover, RET
D707N is unable to bind PKCδ. On the other hand, the C-terminal
RET 707-1017 fragment (IC-RET), contained between the two
caspase-3 consensus sites in the cytoplasmic RET tail, induces
apoptosis independently of the presence of any AIP mutant or rat
Aip siRNA (Fig. 2J). This leads to the conclusion that RET processing
by caspase-3 is the key AIP-related step in the RET-apoptosis
pathway. We note that a kinase-domain point-mutant inactive PKCδ
also prevents RET-induced apoptosis (Fig. 3A).
Our data here regarding the essential role of AIP, as a key
member of the RET-caspase-3 complex, indicates a model where a
full-length RET monomer+ caspase-3+ AIP+ PKCδ complex
assembles which would initiate (i) caspase-3 auto-activation
followed by (ii) RET monomer processing into a shorter fragment
and (iii) activation of PKCδ resulting in activation of the apoptotic
PIT1/p53 pathway. The interaction of this pathway with the
previously described pathways involving cAMP, Galphai-2, phos-
phodiaesterases, mir34 as well as the interactions with multiple
proteins related to the cellular skeleton are currently unclear.
The results in the male rats show the action of deleterious AIP
variants inducing GH excess and resulting gigantism by alteration of
the RET-apoptotic pathway. The phenotype was homogenous for all
Fig. 5 AIP pathogenic mutations injected in the pituitary at birth and expressed in somatotrophs cause acro-gigantism in male rats.
A Chronogram of the model used to test the AIP variants. Retrovirus bearing the empty vector, or expressing wtAIP, or five different AIP
variants (V49M, R304Q, R325Q, C238Y, R16H), followed by an IRES-EGFP expressing element were injected at the pituitary in postnatal day P1.
Two weeks later, animals were randomized. Every week animals were weighed. Some animals were sacrificed 1 or 4 weeks after injection to
study the pituitary gland, while others at week16, when biometric data, together with serum and organ weights, were collected. B 3D whole
organ pituitaries clarified with X-Clarity and studied with light-sheet microscopy one week after the infection of mock virus or wtAIP-IRES-
EGFP virus. Grey: whole organ volume (mock: coronal position respect to light-sheet; wtAIP: axial position respect to light-sheet). EGFP
fluorescence is observed exclusively in the pituitary injected with wtAIP retrovirus throughout the whole organ. AP adenopituitary or
adenohypophysis, IL intermediate lobe, N neuropituitary. C Somatotroph specificity was promoted by the use of retrovirus infecting the most
proliferating cells at this period, that are the somatotrophs, and reinforced by combining the virus with GHRH and ghrelin neuropeptides
inducing somatotroph proliferation. Paraffin sections of mock or wtAIP retrovirus infected four weeks old pituitaries showing confocal GFP
(green) colocalization with PIT1 (nuclear, blue) and GH (red) in somatotroph cells. D Serum Free IGF-1 (FIGF-1) levels in the different groups of
male rats showing that AIP variants but not wtAIP increased significantly and consistently with GH action at its primary target, the liver that
secretes serum IGF-1. E Male rats infected with variant AIP were significantly longer, with longer tail (and longer body, shown in
Supplementary Figure 7). F Soft tissues were enlarged in male animals bearing AIP variants in the pituitary. Significant differences were found
for back and front paws and ears in rats injected with AIP variants. G AIP variants induced cardiomegaly. H Left: Total body weight was
increased but total fat mass presented no differences. Right: Body composition was assessed by EchoMRI. AIP variants significantly increased
lean mass, while fat mass was not affected except for R16H. (One-way ANOVA with Dunnett’s test multiple comparison test correction D-E-F-G-
H. *, p < 0.05; **, p < 0.01; ***, p < 0.001; numbers, when p is non-significant but is small).
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deleterious variants with high IGF-1 (the main GH target hormone in
serum), enhanced length, weight, increase in muscle mass, and
bigger hearts. At the molecular level in the pituitary, pathogenic AIP
reduced caspase-3, IC-RET, PKCδ, and PARP cleavage and activation.
Adenohypophysis areas and reticulin staining in pituitary tissue
showed that altering the RET/apoptosis pathway induces somato-
troph hyperplasia and this is enough for GH/ IGF-1 excess and
gigantism, but not for generating an adenoma within our study
timeframe. This is a key result that could be also important for
pathogenic process in the patients. We could speculate that
pathogenic AIP variants will induce a model of step-by-step
tumorigenesis with the first hyperplasia and later adenomas, and
indeed this is seen both in the animal model and humans. In all three
published mouse models, such as the global Aip heterozygous or the
conditional Gh-specific or Hesx1-specific Aip-knockouts, pituitary
hyperplasia is present many weeks before the appearance of
Fig. 6 AIP pathogenic mutations injected in the pituitary at birth block the RET/caspase-3/PKCδ/PIT1 apoptosis pathway in male rats
inducing hyperplasia. A Left: Microphotographs of immunohistochemistry for cleaved caspase-3, IC-RET (monoclonal RET8D10C9 antibody),
p-PKCδ, and GFP (for EGFP detection) in sections of wt or variant AIP injected pituitaries. Nine sections from three independent animals per
group were mounted in the same slide (20x magnification, bar= 50 μm). Right: Immunohistochemistry was quantified compared to total
nuclei. While there were no significant differences in the % of GFP cells, the % of cleaved caspase-3, IC-RET and p-PKCδ stained cells was
significantly reduced in variant AIP pituitaries respect to wtAIP pituitaries. B Reticulin staining in the same pituitaries as in (A). Partial
disruption of the reticulin network with extended acini is observed (asterisks) in the variant AIP pituitaries. Pituitaries were hyperplastic
(Supplementary Figure 7H). C Protein quantification respect to controls (loading control: beta-actin) of the western blot performed in groups
(n= 4) of pituitary extracts from vector (MIGR1), wtAIP or variant AIP. High throughput gels for 22 samples were used to run extracts in parallel
(Supplementary Figure 6F). Significant reductions in p-PKCδ and p-JNK were found. Cleaved PARP was also reduced in variant AIP pituitaries
except for V49M. PIT1 and IC-RET were significantly reduced in some variants but in other results did not reach significance. Levels of RET, AIP
and exogenous GFP were non-significant between groups. (Kruskall–Wallis with Dunn’s multiple comparison test correction, (A); One-way
ANOVA with Dunnett’s multiple comparison test correction C. *, p < 0.05; **, p < 0.01; numbers, when p is non-significant but is small).
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adenomas [24–27, 69, 70]. Pituitary hyperplasia in humans is not
commonly found, as by the time of clinical presentation tumour
development has usually already occurred. However, there are a few
cases of pituitary hyperplasia described in humans [8] and it also has
been demonstrated around the tumour [71, 72]. How germline
pathogenic AIP variants lead to invasive somatotroph adenomas in
patients is not known and we can only speculate. The RET/GDNF
tyrosine-kinase survival pathway could generate tumour promoting
proliferative events. A subsequent independent genetic event adding
aggressiveness would fit the animal models’ and patients’ data.
The data in female rats show quantitative differences to males.
Females also had a growth phenotype since they are bigger, and
had bigger hyperplastic pituitaries. However, the endocrine
phenotype as young adults is blunted since IGF-1 presented no
differences at 16 weeks, and the pituitary tissue did not show
differences in the RET pathway at that precise moment. It seems
that puberty, earlier in females than in males, is a factor in the
development of gigantism. Probably, this also happens in human
patients since gigantism is more often diagnosed in men than in
women, even in AIP mutated subjects, despite no differences in
Fig. 7 Pituitary adenomas from pituitary-specific Aip-knockout mice or from human patients have overexpression of the RET/GDNF
survival pathway. A Pituitary extracts from15-month old AipFlox/Flox;Hesx1Cre/+ knockout mice compared to AipFlox/Flox;Hesx1+/+ control male
mice. B Increased levels of GDNF, phospho-AKT and phospho-mTOR and reduced expression of phospho-p53 and AIP are found in mutant
animals. C Expression of the CDKN2A probe set, including three probes, in AIP-FIPA pituitary adenomas compared to sporadic pituitary
adenomas, retrieved from ReGEO GSE63357, a study using the Affymetrix HG-U133 Plus 2.0 array. Only 209644_x_at includes oligos specific for
the CDKN2A-ARF specific Exon 1, while the other probes contain oligos specific for the other protein isoform CDKN2A-p16 specific Exon 1
(21156_at), or the common Exon 3 (207039_at). D Immunohistochemistry comparing somatotroph macroadenomas from sporadic (Sp GH) or
AIP-FIPA tumours (AIP+). E Representative stainings for RET (total RET HPA008356), GDNF and GFRα1. Sections were counterstained with
haematoxylin. F Corresponding fields within the same sample, showing heterogeneity of GDNF staining compared to GH. (N= 3;
Mann–Whitney, *p < 0.05; numbers, when p is non-significant but approximates to significant levels).
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the incidence of acromegaly [12, 73], although other gender
differences in pituitary physiology could also play a role.
15 month old AipFlox/Flox;Hesx1Cre/+ mice have established pituitary
adenomas that we have also studied. In relation to the RET-apoptotic
pathway, phospho-p53 was reduced. Hyperactivation of the RET/
GDNF-survival pathway was demonstrated with enhanced GDNF
protein expression, and phospho-RET, phospho-AKT and phospho-
mTOR activation. This pathway would induce proliferation over the
basis of the absence of apoptosis. These results fit well with recent
findings in a long series of human sporadic somatotrophinomas (non
AIP-FIPA) that have demonstrated a six-time increase in GDNF
expression over the normal pituitary, and activation of the RET/
GDNF-survival pathway including AKT/mTOR activation and down-
regulation of p53/PARP activity [30]. In sporadic somatotroph
adenomas, quantitative ARF mRNA expression indicating some
remnants of a functional RET-apoptotic pathway, was a significant
marker of good prognosis and response to first-line therapy (surgery,
somatostatin agonists), while absence of ARF expression indicating
exclusivity of RET/GDNF survival pathway was associated to resistance
to first-line therapy [30]. In that work, small kinase inhibitors able to
inhibit RET/GDNF-induced kinase activity were shown as good
alternative new avenues for treating resistant sporadic adenomas.
Our present results indicate that this approach with anti-RET kinase
inhibitors could even be more successful for treating the FIPA
somatotroph adenomas that are so aggressive and resistant to
surgery and the usual medical therapy with agonists. Reduced levels
of AIP protein have been associated with resistance to somatostatin
analogues in sporadic acromegaly [74]. The human data we present
here suggest that ARF expression levels are downregulated in AIP-
FIPA tumours, indicating the reduced activity of the RET apoptosis
pathway. Corresponding to our data on sporadic somatotroph
tumours [30], this low CDKN2A-ARF RNA expression could also explain
the well-described resistance of AIP-FIPA tumours to first-generation
somatostatin analogues. Moreover, although GDNF was present in the
tumours, its expression was heterogenous, revealing that a combina-
tion of lack of apoptosis (low ARF) and increased RET kinase activity
(GDNF) is playing a dual role in AIP+ tumour samples.
In summary, we have found an explanation of the long-sought
question regarding the tissue and cell-type specificity of AIP-
related tumours. AIP plays an essential role in the initial steps of
the RET-apoptotic pathway in PIT1 expressing cells. Lack of AIP or
pathogenic mutations block this pathway promoting the RET-
survival pathway characteristic of the pituitary somatotrophino-
mas. This connection between AIP and RET has implications for
the aggressive pituitary adenomas observed in the majority of
affected patients with AIP mutations and could be of future use in
alternative therapeutic approaches.
MATERIAL AND METHODS
Extended material and methods are detailed in Supplementary
information.
In silico study of AIP variants
Human AIP variants were analysed using databases and predicting
algorithms, classified by the given in situ threshold and the alternative
threshold proposed in [75].
In vitro experimental design, cell lines and rat
adenohypophysis primary culture
The rat GH4C1 cell line and primary adenohypophysis cells were cultured as
described [2, 3, 76]. Recombinant GDNF (Calbiochem) is obtained from Sf9 fly
cell line, (>97%) and with very low endotoxin contain (LPS ≤ 1.0 EnU/μg).
Apoptosis and Cell counting assays
Apoptosis detection was performed and counted 48 h after treatments as
described [2, 3, 30, 31]. Earlier apoptosis was detected with caspase-3/7
CellEVENT (Thermo).
Lysates, subcellular fractionation, western blot and
immunoprecipitation
Experimental setup for lysates and immunoprecipitations is detailed in
Supplementary Methods [2, 77]. Subcellular fractionation was performed as
[78] with some modifications. For rat pituitary westerns we used Precast
Criterion™ TGX™ (Biorad). Antibodies and dilutions are shown in
Supplementary Information.
Caspase-3 enzyme activity
Cells were lysed with 50 μL Caspase-Glo® 3/7 Assay kit (G8090, Promega)
and measured with Multimode Mithras LB 940 (Berthold Technologies).
Promoter activity
Pit1 promoter activity was measured as described [2, 3, 76].
RNA purification and qRT-PCR
It was performed as described [30]. Primers are listed in Supplementary
Information.
Proximity Ligation Assay (PLA)
We used the in situ technology Duolink® Proximity ligation Assay (PLA)
[38, 39] (Sigma) followed by Fiji-Image J 1.51 [79] and CellProfiler 3.1.8 [80]
software quantification.
In silico exploratory model of protein interaction
An exploratory model of the interaction between AIP, RETS, PKCδ and
caspase-3 based on the results of the PLA assay was carried out with two
softwares SWISS-MODEL and UCSF Chimera [40, 41].
In vivo rat model to functionally evaluate missense AIP
variants in pituitary
Procedures were carried out under the Procedures Act n° 15003/14/005 (to
CVA), granted by Galicia Regional Government, following NC3Rs’ ARRIVE
guidelines. Pups were injected at P1. Hormones and phenotypic measures
are detailed in Supplementary information.
Adenohypophysis immunohistochemistry and
immunofluorescence. Whole pituitary clarification with
X-Clarity. Light-sheet microscopy
Immunohistochemistry in human pituitary adenomas was performed with
EnVision as described [3]. Pituitary clearing was performed with X-CLARITY
(Logos Biosystems) following by analysis with Imaris 9.3 software (Bit-
plane). Ethical approval for human somatotrophinomas stainings was
obtained from Cambridgeshire 1 Research Ethics Committee, Cambridge,
UK (06/Q0104/133).
Pituitary-specific AIP knockout mouse model
Animal studies were performed following the NC3Rs’ ARRIVE guidelines
under Animal Licence Permission No PPL 70/7665, supported by QMUL’s
Ethics Committee. The two lines are derived from C57BL/6J (www.jax.org).
[27, 54].
Data collection and statistical analysis
Statistical analysis was performed using GraphPad Prism 8.0.1 (San Diego,
USA), SPSS Statistics 20 (IBM, USA) and Corel Draw Graphic Suite 2017.
DATA AVAILABILITY
All data generated or analysed during this study are included in this manuscript (and
its supplementary information files).
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